Calbinex is a range of products that contain NP339, NovaBiotics' proprietary antifungal peptide which is a potential safe, effective and resistance-free/limiting therapy for vulvovaginal candidiasis

NP339 is also the novel active API of a new locally-administered treatment for VVC, Calbinex, a solution to recurrent yeast infections which kills rather than inhibiting the growth of Candida albicans, including those already resistant to fluconazole, the most commonly used antifungal against Candida.

Vulvovaginal candidiasis (VVC) is a mucosal infection of the vulva and vagina caused by several Candida spp., but most commonly C. albicans.

With a global RVVC prevalence estimated to be around 138 million women, and the prevalence of VVC therefore significantly higher, there is a large estimated global market for treatment of VVC and RVVC.